<DOC>
	<DOC>NCT02386982</DOC>
	<brief_summary>This study evaluates the beta cell function, pharmacodynamics, pharmacokinetics, safety and tolerability after 4 weeks treatment of 75mgBID or 75mgQD of HMS5552.</brief_summary>
	<brief_title>Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male and female,age 1865 years Has type 2 diabetes mellitus BMI 20 to 29kg/m2 Willingness to adhere to the protocol requirement Patients with type1 diabetes mellitus Received any antidiabetic drug within runin or during screening Hepatic diseases Kidney diseases Clinical abnormal finding in EVG,labs and physical exams Women of childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>